C4 Therapeutics Company Insiders
| CCCC Stock | USD 1.82 0.11 6.43% |
C4 Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding C4 Therapeutics suggests that all insiders are panicking. C4 Therapeutics employs about 110 people. The company is managed by 18 executives with a total tenure of roughly 257 years, averaging almost 14.0 years of service per executive, having 6.11 employees per reported executive.
Insider Sentiment 0
Mostly Selling
Selling | Buying |
Latest Trades
| 2026-01-16 | Leonard Reyno | Disposed 10000 @ 2.22 | View | ||
| 2025-02-18 | Scott N Boyle | Disposed 669 @ 3.15 | View | ||
| 2025-02-14 | Scott N Boyle | Disposed 490 @ 3.15 | View |
Monitoring C4 Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in C4 Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in private. C4 Therapeutics Management Team Effectiveness
The company has return on total asset (ROA) of (0.232) % which means that it has lost $0.232 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5998) %, meaning that it created substantial loss on money invested by shareholders. C4 Therapeutics' management efficiency ratios could be used to measure how well C4 Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of February 8, 2026, Return On Tangible Assets is expected to decline to -0.36. In addition to that, Return On Capital Employed is expected to decline to -0.47. At present, C4 Therapeutics' Fixed Asset Turnover is projected to slightly decrease based on the last few years of reporting.As of February 8, 2026, Common Stock Shares Outstanding is expected to decline to about 53.8 M. The current year's Net Loss is expected to grow to about (109.6 M)C4 Therapeutics secures a total of 96.91 Million outstanding shares. The majority of C4 Therapeutics outstanding shares are owned by institutions. These other corporate entities are usually referred to as non-private investors looking to acquire positions in C4 Therapeutics to benefit from reduced commissions. Hence, outside corporations are subject to a different set of regulations than regular investors in C4 Therapeutics. Please pay attention to any change in the institutional holdings of C4 Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company retains, if the real value of the entity is less than the current market value, you may not be able to make money on it.
Shares in Circulation | First Issued 2019-09-30 | Previous Quarter 71 M | Current Value 73 M | Avarage Shares Outstanding 45 M | Quarterly Volatility 24.1 M |
C4 Therapeutics Workforce Comparison
C4 Therapeutics is number one stock in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 217. C4 Therapeutics totals roughly 110 in number of employees claiming about 51% of equities under Health Care industry.
C4 Therapeutics Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific C4 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on C4 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, C4 Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
C4 Therapeutics Notable Stakeholders
A C4 Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as C4 Therapeutics often face trade-offs trying to please all of them. C4 Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting C4 Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Andrew MBA | President CEO | Profile | |
| Paige Mahaney | Chief Officer | Profile | |
| Kelly Schick | Chief Officer | Profile | |
| Isabel Chiu | Senior Development | Profile | |
| Mr MBA | Chief Officer | Profile | |
| Andrew Hirsch | Pres CEO | Profile | |
| Leonard MD | Chief Officer | Profile | |
| Roy Pollock | Senior Sciences | Profile | |
| Lauren White | Chief Officer | Profile | |
| Christopher Nasveschuk | Senior Chemistry | Profile | |
| Stewart Fisher | Chief Officer | Profile | |
| Courtney Solberg | Senior Relations | Profile | |
| Kendra Adams | Chief Treasurer | Profile | |
| Mayra ReyesArmour | Quality Operations | Profile | |
| Jolie JD | Chief Secretary | Profile | |
| Mark Mossler | Chief Officer | Profile | |
| Nathanael Gray | CoFounder Board | Profile | |
| Kristina Zambouras | Director HR | Profile |
About C4 Therapeutics Management Performance
The success or failure of an entity such as C4 Therapeutics often depends on how effective the management is. C4 Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of CCCC management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the CCCC management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.35) | (0.36) | |
| Return On Capital Employed | (0.45) | (0.47) | |
| Return On Assets | (0.35) | (0.36) | |
| Return On Equity | (0.56) | (0.53) |
Please note, the presentation of C4 Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, C4 Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of C4 Therapeutics' management manipulating its earnings.
C4 Therapeutics Workforce Analysis
Traditionally, organizations such as C4 Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare C4 Therapeutics within its industry.C4 Therapeutics Manpower Efficiency
Return on C4 Therapeutics Manpower
| Revenue Per Employee | 323.5K | |
| Revenue Per Executive | 2M | |
| Net Loss Per Employee | 957.4K | |
| Net Loss Per Executive | 5.9M | |
| Working Capital Per Employee | 1.9M | |
| Working Capital Per Executive | 11.8M |
Complementary Tools for CCCC Stock analysis
When running C4 Therapeutics' price analysis, check to measure C4 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy C4 Therapeutics is operating at the current time. Most of C4 Therapeutics' value examination focuses on studying past and present price action to predict the probability of C4 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move C4 Therapeutics' price. Additionally, you may evaluate how the addition of C4 Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk |